Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) dropped 2.2% during trading on Tuesday . The company traded as low as $6.53 and last traded at $6.64, with a volume of 439,215 shares. The stock had previously closed at $6.79.

RPTP has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Raptor Pharmaceutical Corp. in a research report on Friday, May 6th. FBR & Co restated a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research report on Sunday, June 12th. Finally, Citigroup Inc. cut shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $6.00 to $8.00 in a research report on Monday, August 8th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $7.21.

The firm’s 50-day moving average price is $6.01 and its 200-day moving average price is $5.01. The stock’s market capitalization is $557.05 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. The firm earned $32.05 million during the quarter, compared to analyst estimates of $28.52 million. During the same period last year, the business earned ($0.17) EPS. The firm’s revenue was up 37.4% on a year-over-year basis. On average, equities research analysts forecast that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. boosted its position in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 as of its most recent filing with the SEC.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.